Motif Bio plc (NASDAQ:MTFB)
Industry: Biotechnology

Motif Bio plc, a clinical stage biopharmaceutical company, develops and commercializes pharmaceutical formulations in the United States. The company develops novel antibiotics for the treatment of serious and life-threatening infections caused by multi-drug resistant bacteria. Its lead product candidate is iclaprim, a novel antibiotic that is in Phase III clinical trials to treat bacterial infections, such as acute bacterial skin and skin structure infections, and hospital-acquired bacterial pneumonia caused by methicillin-resistant staphylococcus aureus, as well as to treat lung infections caused by Staphylococcus aureus in patients with cystic fibrosis. Motif Bio plc was incorporated in 2014 and is based in New York, New York.

Current Quote*
Last: $2.152
Change: -0.098
Book: $Unk
Volume: 22,556

As Of: 04/24 13:16 ET
*Quotes delayed by 20min.

Graphs for MTFB


3 Month Graph


6 Month Graph


1 Year Graph